TrialThe lancet. HIV2024

Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study.

Elizabeth D Lowenthal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.